Other researchers have also utilized the PD-1/PD-L1 axis by developing liposomes decorated with multivalent PD-L1-binding peptides, which promoted lysosomal degradation of the PD-L1 molecule on tumor cells upon binding, alleviating PD-L1 mediated T cell suppression [135], or using proprietary small molecule PD1/PD-L1 inhibitors, for instance, BMS-202 [120]. The gene discussed is CD274; the disease is neoplasm.